Anastassova Neda

Dr. Anastassova Neda

Institute of Organic Chemistry with Centre of Phytochemistry, Plovdiv, Bulgaria

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Anastassova NedaAnastassova Neda
Anastassova Neda
DADenitsa Aluani
Denitsa Aluani
NHNadya Hristova-Avakumova
Nadya Hristova-Avakumova
VTVirginia Tzankova
Virginia Tzankova
MKMagdalena Kondeva-Burdina
Magdalena Kondeva-Burdina
Denitsa Y. YanchevaDenitsa Y. Yancheva
Denitsa Y. Yancheva
Oxidative stress is a key contributing factor in the complex degenerating cascade in Parkinson’s disease. The inhibition of MAO-B affords higher dopamine bioavailability and stops ROS formation. The incorporation of hydroxy and methoxy groups in the arylhydrazone moiety of a new series of 1,3-disubstituted benzimidazole-2-thiones could increase the neuroprotective activity. In vitro safety evaluation on SH-SY5Y cells and rat brain synaptosomes showed a strong safety profile. Antioxidant and neuroprotective effects were evaluated in H2O2-induced oxidative stress on SH-SY5Y cells and in a model of 6-OHDA-induced neurotoxicity in rat brain synaptosomes, where the dihydroxy compounds 3h and 3i demonstrated the most robust neuroprotective and antioxidant activity, more pronounced than the reference melatonin and rasagiline. Statistically significant MAO-B inhibitory effects were exerted by some of the compounds where again the catecholic compound 3h was the most potent inhibitor similar to selegiline and rasagiline. The most potent antioxidant effect in the ferrous iron induced lipid peroxidation assay was observed for the three catechols—3h and 3j, 3q. The catecholic compound 3h showed scavenging capability against superoxide radicals and antioxidant effect in the iron/deoxyribose system. The study outlines a perspective multifunctional compound with the best safety profile, neuroprotective, antioxidant and MAO-B inhibiting properties.

1 January 2021 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
Anastassova NedaAnastassova Neda
Anastassova Neda
DADenitsa Aluani
Denitsa Aluani
AKAnton Kostadinov
Anton Kostadinov
MRMiroslav Rangelov
Miroslav Rangelov
NTNadezhda Todorova
Nadezhda Todorova
DYDenitsa Yancheva
Denitsa Yancheva
Neuroprotective drugs and selective monoamine oxidase inhibitors can slow down the progression and improve symptoms of Parkinson’s disease (PD). Since there is an implication of oxidative stress in the pathophysiological mechanisms of the disease, the compounds possessing an ability to reduce the oxidative stress are prime candidates for neuroprotection. Thereby our current study is focused on the development of new multi-target PD drugs capable of inhibiting the activity of monoamine oxidase-B while exerting neuroprotective and antioxidant properties. A small series of benzimidazole derivatives containing hydroxy and methoxy arylhydrazone fragments has been synthesized and the neurotoxicity of the compounds has been evaluated in vitro on neuroblastoma SH-SY5Y cells and on isolated rat brain synaptosomes by measuring the cell viability and the levels of reduced glutathione and a good safety profile has been shown. The 2-hydroxy-4-methoxy substituted arylhydrazone 7 was the least toxic on neuronal SH-SY5Y cells and showed the lowest neurotoxicity in rat brain synaptosomes. The neuroprotective properties of the test compounds were further assessed using two models: H2O2-induced oxidative stress on SH-SY5Y cells and 6-hydroxydopamine-induced neurotoxicity in rat brain synaptosomes. Compound 7 showed more pronounced neuroprotective activity on SH-SY5Y cells, compared to the referent melatonin and rasagiline. It also preserved the synaptosomal viability and the reduced glutathione levels; the effects were stronger than those of rasagiline and comparable to melatonin. All the tested compounds were capable to inhibit human monoamine oxidase-B enzyme to a significant extent, however, compound 7 exerted the most prominent inhibitory activity, similar to selegiline and rasagiline. The carried out molecular docking studies revealed that the activity is related to the appropriate molecular structure enabling the ligand to enter deeper in the narrow and highly lipophylic active site pocket of the human monoamine oxidase-B and has a favoring interaction with the key amino acid residues Tyr326 and Cys172. Since much scientific evidence points out the implication of iron dyshomeostasis in PD, the compounds were tested to reduce the ferrous iron induced oxidative molecular damage on biologically important molecules in an in vitro lecithin containing model system. All the investigated compounds denoted protection effect, stronger than the one of the referent melatonin. In order to support the assignments of the significant neuroprotective and antioxidant pharmacological activities, the radical-scavenging mechanisms of the most promising compound 7 were evaluated using DFT methods. It was found that the most probable free radicals scavenging mechanism in nonpolar phase is the hydrogen atom transfer from the amide group of compound 7, while in polar medium the process is expected to occur by a proton transfer. The current study outlines a perspective leading structure, bearing the potential for a new anti-PD drug. All performed procedures were approved by the Institutional Animal Care Committee of the Medical University of Sofia (Bulgarian Agency for Food Safety with Permission № 190, approved on February 6, 2020).

21 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
Anastassova NedaAnastassova Neda
Anastassova Neda
DSDenitsa Stefanova
Denitsa Stefanova
NHNadya Hristova-Avakumova
Nadya Hristova-Avakumova
IGIrina Georgieva
Irina Georgieva
MKMagdalena Kondeva-Burdina
Magdalena Kondeva-Burdina
Denitsa Y. YanchevaDenitsa Y. Yancheva
Denitsa Y. Yancheva
In light of the known neuroprotective properties of indole compounds and the promising potential of hydrazone derivatives, two series of aldehyde-heterocyclic hybrids combining those pharmacophores were synthesized as new multifunctional neuroprotectors. The obtained derivatives of indole-3-propionic acid (IPA) and 5-methoxy-indole carboxylic acid (5MICA) had good safety profiles: Hemolytic effects < 5% (200 μM) and IC50 > 150 µM were found in the majority of the SH-SY5Y and bEnd3 cell lines. The 2,3-dihydroxy, 2-hydroxy-4-methoxy, and syringaldehyde derivatives of 5MICA exhibited the strongest neuroprotection against H2O2-induced oxidative stress in SH-SY5Y cells and 6-OHDA-induced neurotoxicity in rat-brain synaptosomes. All the compounds suppressed the iron-induced lipid peroxidation. The hydroxyl derivatives were also the most active in terms of deoxyribose-degradation inhibition, whereas the 3,4-dihydroxy derivatives were able to decrease the superoxide-anion generation. Both series of compounds showed an increased inhibition of hMAO-B, with greater expression detected in the 5MICA hybrids. The in vitro BBB model with the bEnd3 cell line showed that some compounds increased the permeability of the endothelial monolayer while maintaining the tight junctions. The combined results demonstrated that the derivatives of IPA and 5MICA showed strong neuroprotective, antioxidant, MAO-B inhibitory activity and could be considered as prospective multifunctional compounds for the treatment of neurodegenerative disorders.

3 March 2020 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
Anastassova NedaAnastassova Neda
Anastassova Neda
Denitsa Y. YanchevaDenitsa Y. Yancheva
Denitsa Y. Yancheva
NHNadya Hristova-Avakumova
Nadya Hristova-Avakumova
VHVera Hadjimitova
Vera Hadjimitova
TTTrayko Traykov
Trayko Traykov
MKMagdalena Kondeva-Burdina
Magdalena Kondeva-Burdina

11 March 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
Anastassova NedaAnastassova Neda
Anastassova Neda
MKMagdalena Kondeva-Burdina
Magdalena Kondeva-Burdina
NHNadya Hristova-Avakumova
Nadya Hristova-Avakumova
DSDenitsa Stefanova
Denitsa Stefanova
MRMiroslav Rangelov
Miroslav Rangelov
DYDenitsa Yancheva
Denitsa Yancheva

3 December 2024 in Molecules
Verified
Journal Article
Open access
PDF file
PPPolina Petkova-Kirova
Polina Petkova-Kirova
Anastassova NedaAnastassova Neda
Anastassova Neda
BMBorislav Minchev
Borislav Minchev
DUDiamara Uzunova
Diamara Uzunova
VGValya Grigorova
Valya Grigorova
LTLyubka Tancheva
Lyubka Tancheva
Alzheimer’s disease (AD) has long proven to be a complex neurodegenerative disorder, with cholinergic dysfunction, oxidative stress, and neuroinflammation being just a few of its pathological features. The complexity of the disease requires a multitargeted treatment covering its many aspects. In the present investigation, an arylhydrazone derivative of 5-methoxyindole-2-carboxylic acid (5MeO), with in vitro strong antioxidant, neuroprotective and monoamine oxidase B-inhibiting effects, was studied in a scopolamine-induced Alzheimer-type dementia in rats. Using behavioral and biochemical methods, we evaluated the effects of 5MeO on learning and memory, and elucidated the mechanisms of these effects. Our experiments demonstrated that 5MeO had a beneficial effect on different types of memory as assessed by the step-through and the Barnes maze tasks. It efficiently restored the decreased by scopolamine brain-derived neurotrophic factor and acetylcholine levels and normalized the increased by scopolamine acetylcholine esterase activity in hippocampus. Most effective 5MeO was in counteracting the induced by scopolamine oxidative stress by decreasing the increased by scopolamine levels of lipid peroxidation and by increasing the reduced by scopolamine catalase activity. Blood biochemical analyses demonstrated a favorable safety profile of 5MeO, prompting further pharmacological studies suggesting 5MeO as a safe and efficient candidate in a multitargeted treatment of AD.